Stopping GLP-1s and keeping weight off: what's realistic?

What's this video probably claiming?

Based on the caption, @tailor.jewel is describing a personal arc that a lot of people on GLP-1 forums will recognize: she stopped semaglutide (sold as Ozempic, though that's technically the diabetes-labeled version) because of side effects, then found a different approach, presumably through @MINAZALIE, that helped her lose weight and maintain that loss. The implicit claim here is two-part. First, that stopping a GLP-1 doesn't have to mean regaining weight. Second, that whatever she did instead worked better, or at least more sustainably, for her. She's not making a peer-reviewed argument, but the video will almost certainly be read by viewers as evidence that GLP-1s aren't necessary for lasting weight loss, and that an alternative path exists. That framing deserves scrutiny.

What does the science actually show?

The weight regain data after stopping GLP-1s is not subtle. The STEP 4 trial (Rubino et al., 2021, JAMA) followed participants who had lost weight on semaglutide 2.4 mg and then either continued or switched to placebo. The placebo group regained roughly two-thirds of their prior weight loss within 48 weeks. A 2022 follow-up analysis from the SURMOUNT-4 trial looking at tirzepatide showed similar patterns. The biology isn't mysterious: GLP-1 receptor agonists reduce appetite by acting on hypothalamic receptors and slowing gastric emptying. When you stop the drug, those mechanisms revert. Obesity is a chronic disease with hormonal and neurological underpinnings, not a problem you solve by temporarily suppressing appetite. Can some people maintain weight loss after stopping? Yes. But they are the minority, and the published literature does not support a narrative that lifestyle-based alternatives reliably replicate what these medications do at the receptor level.

Where does the social media noise diverge from clinical reality?

TikTok's GLP-1 conversation has a structural bias toward people who either loved the drugs or hated them enough to make a video about it. The people who quietly stayed on semaglutide, tolerated it fine, and lost 15 percent of their body weight, which is the average seen in STEP 1 (Wilding et al., 2021, NEJM), are not posting transformation content. The people who stopped, regained, and feel embarrassed are not posting either. What you see is a curated slice. The side effect complaints driving videos like this one are real: nausea, vomiting, and gastroparesis-adjacent symptoms affect a meaningful portion of users, particularly in the early titration phase. But the answer to intolerable side effects is usually dose adjustment or switching agents, not abandoning the therapeutic class entirely. The framing that a creator's program replaced pharmaceutical-grade receptor agonism is almost certainly overstated, even if that creator's advice on nutrition or behavior is genuinely useful.

What should you actually know?

If you stopped a GLP-1 because of side effects, that is a legitimate medical decision, and you are not obligated to stay on any medication. But you should go in with accurate expectations. A 2023 analysis in Obesity Reviews (Sarma et al.) found that behavioral interventions alone produce average weight losses of 3 to 5 percent of body weight, compared to 10 to 20 percent with GLP-1 therapy depending on the agent. Maintenance after drug discontinuation is possible but requires aggressive dietary and behavioral support, and most people without that infrastructure regain. If someone on TikTok is selling a program as an Ozempic replacement, ask what the actual evidence base is for that program specifically, not just for lifestyle interventions in general. The distinction matters. A regulated telehealth provider can help you figure out whether restarting at a lower dose, switching to a different agent, or pursuing a structured behavioral program with realistic weight goals makes sense for your situation.